changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
This case was impressive because of the clear visualization of the tumor and the embolized vessels on the post-embolization non-contrast CBCT, in addition to the complete response of the related lesions.
After 4 weeks of follow-up, a complete response on mRECIST was demonstrated with a decrease in tumor size to 0.9 mm.
The radiopaque property of LC Bead LUMI™ allows for accurate needle placement and full lesion ablation. If the lesion cannot be seen on non-contrast CT, there is a possibility that the lesion may not be fully ablated.
A Retrospective Study of Medicare claim ...
Arizona Patients Successfully Receive th...
Recommended Cash Offer for BTG plc by Bo...
One-year results of ACCESS PTS study bri...
OPTALYSE PE Results Presented at Society...
Health Canada approves radiopaque bead f...